Patients colonized with AMR pathogens showed high risk for infection with the same pathogen for up to 2 years, indicating a time window for decolonization interventions.

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday.

Ondine’s innovative light-activated antimicrobial treatment has the potential to become the first FDA-approved nasal decolonization treatment for the prevention of surgical site infections. The ...